QUINJA

Browse PDR's full list of drug information

QUINJA

Classes

Topical Dermatological Antifungals
Topical Scalp Antifungals

Administration
Topical Administration Other Topical Formulations

Apply a thin film sparingly to the affected area.
Do not cover with an occlusive dressing.
Do not apply topical gel to eyes.

Adverse Reactions
Mild

pruritus / Rapid / Incidence not known
skin discoloration / Delayed / Incidence not known
urticaria / Rapid / Incidence not known
hair discoloration / Delayed / Incidence not known
diarrhea / Early / Incidence not known
abdominal pain / Early / Incidence not known
vomiting / Early / Incidence not known
nausea / Early / Incidence not known
headache / Early / Incidence not known
fever / Early / Incidence not known
vertigo / Early / Incidence not known
chills / Rapid / Incidence not known

Common Brand Names

QUINJA

Dea Class

Rx

Description

Topical preparation used to treat skin infections and eczema.

Dosage And Indications
For the treatment of contact dermatitis, atopic dermatitis, impetiginized eczema/ impetigo, nummular eczema, endogenous chronic infectious dermatitis, stasis dermatitis, pyoderma, nuchal eczema, chronic eczematoid otitis externa, acne urticata, localized or disseminated neurodermatitis, lichen simplex chronicus, anogenital pruritus (vulvus, scrotum, anus), folliculitis, bacterial dermatoses, mycotic dermatoses (tinea capitis, tinea cruris, tinea corporis, tinea pedis), monliasis, and intertrigo.
NOTE: Indications are based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug; the indications are listed as "possibly” effective.]
 Topical dosage Adults, Adolescents, and Children >= 12 years

Apply to affected area(s) 3 to 4 times daily or as directed by a physician.

Dosing Considerations
Hepatic Impairment

Specific guidelines for dosage adjustments in hepatic impairment are not available. Oral iodoquinol is contraindicated in patients with hepatic insufficiency; however, use of the topical preparation would not be expected to yield significant systemic concentrations. Use with caution.

Renal Impairment

Specific guidelines for dosage adjustments in renal impairment are not available; it appears that no dosage adjustments are needed.

Drug Interactions

There are no drug interactions associated with Aloe Polysaccharide; Iodoquinol products.

How Supplied

QUINJA Topical Gel: 1.25-1%

Maximum Dosage
Adults

Maximum dosage information is not available.

Elderly

Maximum dosage information is not available.

Adolescents

Maximum dosage information is not available.

Children

>= 12 years: Maximum dosage information is not available.
< 12 years: Safety and efficacy have not been established.

Infants

Safety and efficacy have not been established.

Mechanism Of Action

Mechanism of Action: The mechanism of activity of aloe polysaccharide; iodoquinol is unknown. Iodoquinol has antifungal and antibacterial activity.

Pharmacokinetics

Aloe polysaccharide; iodoquinol is administered topically. Pharmacokinetic data are not available.

Pregnancy And Lactation
Pregnancy

No adequate and well-controlled studies have been conducted in pregnant individuals and its ability to cause fetal harm or affect reproductive capacity is unknown. Animal reproductive studies have not been conducted with topical iodoquinol; aloe. There have been limited case reports of oral iodoquinol used during pregnancy without apparent harm to the fetus. Iodoquinol contains 64% organically bound iodine, and the fetus is potentially susceptible to iodine-induced thyroid disorders or other potential iodoquinol side effects. It is unknown if topical use of iodoquinol could result in significant maternal or fetal concentrations. Administer during pregnancy only when clearly needed.

Data are limited regarding use of aloe polysaccharide; iodoquinol during breast-feeding and its' excretion in human breast milk is unknown. Elevated iodine concentrations in the breast-fed infant are theoretically possible, and neonates are among those persons susceptible to iodine-induced thyroid disorders. Consider the benefits of breast-feeding, the risk of potential infant drug exposure, and the risk of an untreated or inadequately treated condition. If a breast-feeding infant experiences an adverse effect related to a maternally administered drug, health care providers are encouraged to report the adverse effect to the FDA.